NHS

**St Helens and Knowsley
Teaching Hospitals**
NHS Trust

Ref. No:	090190522
From:	Commercial
Date:	19/05/22
Subject:	Intra-vitreal treatments in Ophthalmology

REQUEST & RESPONSE

1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:
- Aflibercept   297
- Bevacizumab   This drug is not used
- Brolucizumab   <5
- Dexamethasone   28
- Ranibizumab   414

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
- Aflibercept   46
- Bevacizumab   This drug is not used
- Brolucizumab   This drug is not used
- Dexamethasone   8
- Ranibizumab   91

3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:
- Aflibercept   35
- Bevacizumab   This drug is not used
- Dexamethasone   <5
- Ranibizumab   43

4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:
- Aflibercept   19
- Bevacizumab   This drug is not used
- Dexamethasone   6
- Ranibizumab   94

These requests are for the number of patients not the number of injections each patient underwent.

Section 40 – Personal Information

Please note that we are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances, sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed "lawfully, fairly and in a transparent manner". It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.